Freenome Initiates Clinical Study of Blood Test for Early Lung Cancer Screening
Freenome’s PROACT LUNG study is intended to validate the clinical performance of its blood test for lung cancer screening.
Read MorePosted by Andy Lundin | Dec 13, 2023 | Lung Cancer |
Freenome’s PROACT LUNG study is intended to validate the clinical performance of its blood test for lung cancer screening.
Read MorePosted by Andy Lundin | Dec 13, 2023 | Lung Cancer |
DELFI Diagnostics is supporting the recently introduced Lung Cancer Screening and Prevention Act (H.R. 6693).
Read MorePosted by Andy Lundin | Dec 12, 2023 | Lung Cancer |
Liquid biopsies could predict which lung cancer patients are responding to immunotherapies or may develop immune-related side effects.
Read MorePosted by Andy Lundin | Dec 1, 2023 | Lung Cancer, Swabs |
Clinical validation data shows that Veracyte’s Percepta Nasal Swab test determines lung cancer risk with high accuracy for certain patients.
Read MorePosted by Andy Lundin | Oct 23, 2023 | Lung Cancer, Molecular Diagnostics |
NeXT Personal ctDNA assay shown to be more sensitive and predictive of clinical outcomes in early-stage lung cancer patients
Read More